Evaluation of neoadjuvant chemotherapy combined with PD-1 inhibitors in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma: a comparative study of antitumor activity-Reference-Cited by-同舟云学术

Evaluation of neoadjuvant chemotherapy combined with PD-1 inhibitors in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma: a comparative study of antitumor activity

Published:2023-10-14 Issue:12 Volume:72 Page:4209-4219
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Xu Pengfei,Fang Qi,Zhao Zheng,Cao Fei,Wu Di,Liu Xuekui

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-023-03557-6.pdf

Reference31 articles.

1. Psyrri A, Fayette J, Harrington K et al (2023) Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: Kestrel, a randomized, open-label, phase III study. Ann Oncol 34:262–274. https://doi.org/10.1016/j.annonc.2022.12.008

2. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6:92. https://doi.org/10.1038/s41572-020-00224-3

3. Chen S, Yang Y, Wang R, Fang J (2023) Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy had a higher ORR than mono-immunotherapy in untreated HNSCC: Meta-analysis. Oral Oncol 145:106479. https://doi.org/10.1016/j.oraloncology.2023.106479

4. Bhatia A, Burtness B (2023) Treating head and neck cancer in the age of immunotherapy: a 2023 update. Drugs 83:217–248. https://doi.org/10.1007/s40265-023-01835-2

5. Chow LQM (2020) Head and neck cancer. N Engl J Med 382:60–72. https://doi.org/10.1056/NEJMra1715715

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-1 inhibitor combined with paclitaxel and cisplatin in the treatment of recurrent and metastatic hypopharyngeal/laryngeal squamous cell carcinoma: efficacy and survival outcomes;Frontiers in Immunology;2024-05-17